Candida in IBD: Friend or Foe?

Julia Fritsch; Maria T Abreu

doi:10.1016/j.chom.2020.04.018

Candida in IBD: Friend or Foe?

Cell Host Microbe. 2020 May 13;27(5):689-691. doi: 10.1016/j.chom.2020.04.018.

Authors

Julia Fritsch¹, Maria T Abreu²

Affiliations

¹ Crohn's and Colitis Center, Division of Gastroenterology, Department of Medicine, University of Miami Leonard Miller School of Medicine, Miami, FL, USA.
² Crohn's and Colitis Center, Division of Gastroenterology, Department of Medicine, University of Miami Leonard Miller School of Medicine, Miami, FL, USA. Electronic address: mabreu1@med.miami.edu.

PMID: 32407705
DOI: 10.1016/j.chom.2020.04.018

Abstract

In this issue of Cell Host & Microbe, Leonardi et al. demonstrate ulcerative colitis patients with high Candida responded best to fecal microbial transplant (FMT). However, decreased Candida post-treatment was associated with improved disease-suggesting that Candida reductions are associated with less inflammation. Pre-FMT Candida levels may identify FMT responders.

Publication types

Comment

MeSH terms

Candida
Colitis, Ulcerative*
Fecal Microbiota Transplantation*
Humans
Inflammation